SCHEMBL2356142

SCHEMBL2356142

CC(O)c1ccccc1Oc1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SLC6A4 P31645 5/20 0.49
HTR2A P28223 4/20 0.49
LMNA P02545 3/20 0.44
L3MBTL1 Q9Y468 2/20 0.44
POLB P06746 1/20 0.44
RHEB Q15382 1/20 0.43
CTNNB1 P35222 1/20 0.43
LTA4H P09960 1/20 0.42
TSHR P16473 1/20 0.42
TSPO P30536 1/20 0.42
ALDH1A1 P00352 2/20 0.42
MAPK1 P28482 1/20 0.42
HTT P42858 1/20 0.42
RIPK1 Q13546 1/20 0.42
SLC6A2 P23975 1/20 0.42
HPGD P15428 1/20 0.42
GAA P10253 1/20 0.41
KMT2A Q03164 1/20 0.41
KCNH2 Q12809 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15515907 0.98 SLC6A4 (0.47) SLC6A4HTR2ALMNAL3MBTL1POLB
SCHEMBL4440523 0.87 P2RX3 (0.42) SLC6A4HTR2ALMNAALDH1A1SLC6A2
SCHEMBL14047222 0.87 HTR2A (0.66) SLC6A4HTR2ALMNAL3MBTL1POLB
SCHEMBL6682183 0.83 SLC6A4 (0.51) SLC6A4HTR2ALMNAL3MBTL1POLB
SCHEMBL11286435 0.83 LTA4H (0.46) SLC6A4HTR2ALMNAL3MBTL1POLB
SCHEMBL8782184 0.83 ADRA2A (0.50) SLC6A4HTR2ALMNAL3MBTL1POLB
Hydrochloric Acid SCHEMBL10409546 0.82 ALDH1A1 (0.52) SLC6A4HTR2ALMNAL3MBTL1POLB
SCHEMBL10874836 0.81 MAOB (0.51) SLC6A4HTR2APOLBALDH1A1GAA
SCHEMBL14138652 0.81 ALDH1A3 (0.46) SLC6A4HTR2ALMNAL3MBTL1ALDH1A1
SCHEMBL1004681 0.80 SLC6A4 (0.49) SLC6A4HTR2ALMNAL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120079434-A Tubular C3N4Heterojunction catalyst and preparation method and application thereof 中国矿业大学 2025-06-03 CN claimed
CN-118108586-A Method for producing benzaldehyde, phenyl formate and phenol by photocatalysis of 2-phenoxy-1-phenyl ethanol 河南师范大学 2024-05-31 CN claimed
CN-112920231-A Method for preparing aromatic compound by visible light photocatalysis lignin 北京化工大学 2021-06-08 CN claimed
CN-120079434-A Tubular C3N4Heterojunction catalyst and preparation method and application thereof 中国矿业大学 2025-06-03 CN disclosed
CN-118108586-A Method for producing benzaldehyde, phenyl formate and phenol by photocatalysis of 2-phenoxy-1-phenyl ethanol 河南师范大学 2024-05-31 CN disclosed
CN-118108586-A Method for producing benzaldehyde, phenyl formate and phenol by photocatalysis of 2-phenoxy-1-phenyl ethanol 河南师范大学 2024-05-31 CN disclosed
CN-118108586-A Method for producing benzaldehyde, phenyl formate and phenol by photocatalysis of 2-phenoxy-1-phenyl ethanol 河南师范大学 2024-05-31 CN disclosed
CN-113698338-B Preparation method of styrene double oxidation product 湖北工业大学 2023-05-16 CN disclosed
CN-112876355-B Method for preparing carboxylic ester compound by breaking carbon-carbon bond through oxidation of secondary alcohol compound 中国科学院大连化学物理研究所 2022-03-08 CN disclosed
CN-113698338-A Preparation method of styrene double oxidation product 湖北工业大学 2021-11-26 CN disclosed
CN-112920231-A Method for preparing aromatic compound by visible light photocatalysis lignin 北京化工大学 2021-06-08 CN disclosed
WO-2014039002-A1 CLEAVAGE OF A B-O-4 BOND IN ETHERS KAT2BIZAB (SE) 2014-03-13 WO disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-8008525-B2 For the 14273 peroxisome proliferator activated receptor; antidiabetic agents, hyperlipidemia, obesity or anorexia; receptor binding assay; drug screening kits TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2011-08-30 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
US-20080167378-A1 Receptor Function Regulation Agent TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2008-07-10 US disclosed
EP-1688138-A1 RECEPTOR FUNCTION REGULATING AGENT Takeda Pharmaceutical Company Limited (JP) 2006-08-09 EP disclosed
WO-2002004411-A1 METHODS FOR PROTECTION OF STRATIFIED SQUAMOUS EPITHELIUM AGAINST INJURY BY NOXIOUS SUBSTANCES AND NOVEL AGENTS FOR USE THEREFOR THE ADMINISTRATORS OF THE TULANE EDUCATIONAL FUND (US) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080167378-A1 Receptor Function Regulation Agent GPR119, INSR, GPR88 SLC6A4 1453/4885HTR2A 328/4885LMNA 4000/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.